Trius Announces Results From Phase 1 Clinical Trial Of Intravenous Torezolid Phosphate
Tuesday, March 30th, 2010We recommend: generic azithromycin, generic bupropion, generic buspirone
Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry
e-mail to a protagonist pressman well-disposed panorama / publish opinions
Trius Therapeutics, Inc. proclaimed results from its Phase 1 clinical test evaluating the safe, tolerability and pharmacokinetics of the endovenous (IV) dose configuration of torezolid orthophosphate, an IV and orally administered irregular propagation oxazolidinone for the discussion of good gm cocksure infections, including methicillin-resistant Staphylococcus aureus ( MRSA ). The tribulation achieved its main finish of establishing the guard and tolerability of the 200 mg IV zen of torezolid orthophosphate to be ill-used in Trius’ forthcoming Phase 3 clinical trials. The field too demonstrated heights unwritten bioavailability of torezolid orthophosphate. Trius believes that these results, conjugated with information from the anterior Phase 1 and Phase 2 clinical trials of the unwritten dose cast of torezolid orthophosphate, supply the clinical base for Trius to move with its Phase 3 clinical trials aforethought for the sec one-half of 2010.
